Figure 1: 6-minute Walk Distance (meters) Mean Change From Baseline, With 95% Confidence Intervals (Tadalafil Fig1)
Tadalafil Tablet
Product Images NDC 65862-880
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 65862-880). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Tadalafil Fig2)
This is a table of coadministered drugs that may interact with Tadalafil (Cialis) by affecting its pharmacokinetics. The drugs are grouped under the class of OYP3A inhibitors or inducers, antacids, and H2 antagonists. The table provides information on the change in Cmax (maximum plasma concentration) and fold change in Tadalafil when coadministered with these drugs. The text also includes recommendations on whether to avoid using Tadalafil with these drugs or if a dose adjustment is required. The last row shows a graph of the fold change in Tadalafil when coadministered with these drugs.*
Figure 3: Kaplan-meier Plot Of Time To Clinical Worsening (Tadalafil Fig3)
This text appears to be a drug compatibility chart. The chart includes different drugs and their effects when co-administered with other substances. The chart includes information on drug substrates, recommended fold change and 90% CI, bleeding time changes, and dose adjustments. However, some of the words are cut off or incomplete, which makes the chart difficult to interpret without more context.*
Package Label-principal Display Panel (20 mg (60 Tablets Bottle))
The text contains a table showing mean change from baseline in meters for a placebo group and a group receiving tadalafil 40mg. The table appears to have three columns labeled "Fo- Piacebo (n-s2)", "@— Tadalafil 40 mg", and "0152 0084 0004". The data suggests that the group receiving tadalafil 40mg had a greater mean change from baseline compared to the placebo group. No further information is available in the text.*
Tadalafil Fig5
This appears to be a table with data related to a study or clinical trial evaluating the effects of a medication called Tadalafil 40mg and its impact on subjects with pulmonary arterial hypertension (PAH). The table includes information on the number of subjects, their baseline 6-minute walk distance, gender, and baseline WHO functional class. Information is also provided on the type of PAH etiology and whether the subjects were using bosentan. The table includes a graph showing the placebo-adjusted mean change in 6-minute walk distance for Tadalafil 40mg, but no units of measurement are provided. Additional context or data is needed to provide a more detailed description of the study's methodology, results, or implications.*
Tadalafil Fig6
Tadalafil Fig7
This appears to be a label of Tadalafil Tablets. The usual dosage is taking two tablets of 20mg once every day. The label also includes warnings to keep the medication out of reach of children and to store at a controlled room temperature. The label has a product code of P1420212 and was manufactured by Aurbindo Pharma in the USA. There is some illegible text on the label, but the drug name and strength are discernible.*
Chemical Structure (Tadalafil Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
